Adaptimmune Therapeutics Plc ADR (ADAPY)

$0.05 0.00 (-1.82%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 45,989,301
Avg Vol 115,232,406
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 15%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
stockCryptoHunter
stockCryptoHunter Dec. 21 at 5:23 PM
$ADAPY What Institutional Holding Really Means Large, reputable firms do not hold OTC-traded biotech stocks by accident. Firms like: • UBS Asset Management • Renaissance Technologies • Morgan Stanley • Bank of America • Jane Street • Long Focus Capital • Ecor1 Capital (biotech-focused) all have strict risk controls, compliance rules, and research teams. 👉 If ADAPY were considered dead, non-viable, or without a future, these firms would have exited completely, especially after delisting.
0 · Reply
US_Bull
US_Bull Dec. 21 at 4:53 PM
$ADAPY Also note they keep laying off their UK associated employees, while their US-based employees residing in Philly were given a chance to transfer to USWorldmeds. So it appears they have put their Jubilee 60 office space in the UK to be subleased (maybe to save costs) and under Navyyard directory USWorldmeds has taken over 351 Rouse Blvd address. Pretty obvious to me where this is headed.
2 · Reply
US_Bull
US_Bull Dec. 21 at 3:25 PM
$ADAPY UBS Group AG holding after the delisting they started a big position. As far as I can see the biggest tute increase after the delisting.
1 · Reply
US_Bull
US_Bull Dec. 21 at 3:00 PM
$ADAPY Fair value of the market cap is multiples of the current artificially suppressed MC due to the following catalysts I am expecting in Q1, H1, 2026: i) Phase 1 data Prame (Has shown effective tumor killing activity https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/255/adaptimmune-selects-adp-600-as-clinical-candidate-for); ii) Phase 1 data CD70 (New publication from 2025 https://pubmed.ncbi.nlm.nih.gov/40519930/ only CD70 targeting T-cell receptor construct out there that targets hematological and solid tumors with IL-15 co-expression); iii) Lete-cel BLA submission any day now and likely fast tracked approval in 2026 with far greater efficacy than Tecelra and expanded patient population at which point regulatory milestone payments are kicking in. The above if + which may very likely be will take the stock up multiples imo. Current SP is nowhere real reflection of the company value. Though my theory is still USWorldmeds may likely want to buy out the remaining assets. They need the in-house GT expertise, which they don't have.
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:27 PM
$ADAPY So the below is of course incorrect and wrong.
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:08 PM
$ADAPY A list of penny stocks many of them in line with us with some trading in green but still the overall trend is market is in a risk off mode on risky assets and then they sell penny stocks first. https://www.tradingview.com/markets/stocks-usa/market-movers-penny-stocks/
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:03 PM
$ADAPY As I was saying nothing specific to ADAPY. Long and strong I am gonna see this to completion:
1 · Reply
MuzunguZanz
MuzunguZanz Dec. 20 at 4:47 AM
$ADAPY I guess we have to wait now for any further development. We either make some money or we sink the investment. I was hoping for SP movement before YE but nothing happened.
1 · Reply
Herre62
Herre62 Dec. 20 at 3:02 AM
$ADAPY That Podcast was prepared on or before Oct 19 . 2025 … Actually anyone who listen carefully that is a warning .. that podcast was prepared without Nasdaq de listing , and no earning and no more deadline will published .. said Prame and Cd70 are still preclinical and long way to go … if good results are comes then good high risk , high reward … but years away … we are talking 3 to 5 years …
0 · Reply
stockCryptoHunter
stockCryptoHunter Dec. 20 at 2:45 AM
$ADAPY Markets are short-term noise, but progress doesn’t stop. If this week wasn’t the move, there’s always next week — and the next catalyst. With key milestones ahead and studies nearing completion, patience here can be rewarded. Strong hands know excitement in biotech often comes when you least expect it. 📈🧬 Staying calm. Staying focused. Staying ready.
0 · Reply
Latest News on ADAPY
No data available.
stockCryptoHunter
stockCryptoHunter Dec. 21 at 5:23 PM
$ADAPY What Institutional Holding Really Means Large, reputable firms do not hold OTC-traded biotech stocks by accident. Firms like: • UBS Asset Management • Renaissance Technologies • Morgan Stanley • Bank of America • Jane Street • Long Focus Capital • Ecor1 Capital (biotech-focused) all have strict risk controls, compliance rules, and research teams. 👉 If ADAPY were considered dead, non-viable, or without a future, these firms would have exited completely, especially after delisting.
0 · Reply
US_Bull
US_Bull Dec. 21 at 4:53 PM
$ADAPY Also note they keep laying off their UK associated employees, while their US-based employees residing in Philly were given a chance to transfer to USWorldmeds. So it appears they have put their Jubilee 60 office space in the UK to be subleased (maybe to save costs) and under Navyyard directory USWorldmeds has taken over 351 Rouse Blvd address. Pretty obvious to me where this is headed.
2 · Reply
US_Bull
US_Bull Dec. 21 at 3:25 PM
$ADAPY UBS Group AG holding after the delisting they started a big position. As far as I can see the biggest tute increase after the delisting.
1 · Reply
US_Bull
US_Bull Dec. 21 at 3:00 PM
$ADAPY Fair value of the market cap is multiples of the current artificially suppressed MC due to the following catalysts I am expecting in Q1, H1, 2026: i) Phase 1 data Prame (Has shown effective tumor killing activity https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/255/adaptimmune-selects-adp-600-as-clinical-candidate-for); ii) Phase 1 data CD70 (New publication from 2025 https://pubmed.ncbi.nlm.nih.gov/40519930/ only CD70 targeting T-cell receptor construct out there that targets hematological and solid tumors with IL-15 co-expression); iii) Lete-cel BLA submission any day now and likely fast tracked approval in 2026 with far greater efficacy than Tecelra and expanded patient population at which point regulatory milestone payments are kicking in. The above if + which may very likely be will take the stock up multiples imo. Current SP is nowhere real reflection of the company value. Though my theory is still USWorldmeds may likely want to buy out the remaining assets. They need the in-house GT expertise, which they don't have.
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:27 PM
$ADAPY So the below is of course incorrect and wrong.
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:08 PM
$ADAPY A list of penny stocks many of them in line with us with some trading in green but still the overall trend is market is in a risk off mode on risky assets and then they sell penny stocks first. https://www.tradingview.com/markets/stocks-usa/market-movers-penny-stocks/
0 · Reply
US_Bull
US_Bull Dec. 20 at 1:03 PM
$ADAPY As I was saying nothing specific to ADAPY. Long and strong I am gonna see this to completion:
1 · Reply
MuzunguZanz
MuzunguZanz Dec. 20 at 4:47 AM
$ADAPY I guess we have to wait now for any further development. We either make some money or we sink the investment. I was hoping for SP movement before YE but nothing happened.
1 · Reply
Herre62
Herre62 Dec. 20 at 3:02 AM
$ADAPY That Podcast was prepared on or before Oct 19 . 2025 … Actually anyone who listen carefully that is a warning .. that podcast was prepared without Nasdaq de listing , and no earning and no more deadline will published .. said Prame and Cd70 are still preclinical and long way to go … if good results are comes then good high risk , high reward … but years away … we are talking 3 to 5 years …
0 · Reply
stockCryptoHunter
stockCryptoHunter Dec. 20 at 2:45 AM
$ADAPY Markets are short-term noise, but progress doesn’t stop. If this week wasn’t the move, there’s always next week — and the next catalyst. With key milestones ahead and studies nearing completion, patience here can be rewarded. Strong hands know excitement in biotech often comes when you least expect it. 📈🧬 Staying calm. Staying focused. Staying ready.
0 · Reply
stockCryptoHunter
stockCryptoHunter Dec. 20 at 2:42 AM
$ADAPY I rate 9 out of 10 Fucking bullish !! NEED MORE PATIENCE THATS ALL I KNOW . Still we are not at end of the Year . 🔥
0 · Reply
Herre62
Herre62 Dec. 19 at 10:55 PM
$ADAPY @stockCryptoHunter Let me know how did you rate to Youtube ?
0 · Reply
US_Bull
US_Bull Dec. 19 at 9:46 PM
$ADAPY Also below picture is a week old. You can find it on Linkedin if you enter the search term Adaptimmune look at the entrance gravel and dirt looks to me they are packing up their stuff question is for what and to where. Also remember the Rouse 351 Blvd address that is under USWorldmed now. Adaptimmune is not listed in the Navy Yard Philly directory.
0 · Reply
US_Bull
US_Bull Dec. 19 at 9:31 PM
$ADAPY Exactly what I am thinking listen at 8:35 min USWorldmed grabathe whole enchilada https://m.youtube.com/watch?v=b4MBGA35_2c&pp=ygUYYWRhcHRpbW11bmUgdGhlcmFwZXV0aWNz
1 · Reply
MrResurge
MrResurge Dec. 19 at 7:54 PM
ARBB is breaking out right now!! What is happening to ARBB 🤯 This could turn into the craziest runner of the day. Bulls need to keep ARBB on watch immediately. ARBB has only 500k share public float remianing! Also watching $HIMS $LULU $AGMH $ADAPY --
0 · Reply
berat2209
berat2209 Dec. 19 at 7:50 PM
$ADAPY I'm sorry, all hope is lost for this stock.
2 · Reply
US_Bull
US_Bull Dec. 19 at 7:25 PM
$ADAPY From Dec. 3, 2025, yeak ok. https://www.loopnet.co.uk/listing/60-jubilee-ave-milton/36369867/
1 · Reply
US_Bull
US_Bull Dec. 19 at 6:35 PM
$ADAPY My guess is rest of the company and its assets will be gobbled by end of Q1, 2026, either by USWorldmed and go private, which is my most likely scenario or by another company that can see the LT potential of its preclinical assets. GLPG still makes sense given they haven't explicitly abolished their cell therapy pipeline and their uza-cel partnership with USWorldmed would be more streamlined. There is no way you go solo for years without a CSO and a legal counsel after Bertrand retired from the company. Also during first asset purchase tons of employees treansferred to USWorldmed.
1 · Reply
US_Bull
US_Bull Dec. 19 at 6:28 PM
$ADAPY https://www.nasdaq.com/market-activity/stocks/adapy/institutional-holdings?page=1&rows_per_page=10
0 · Reply
US_Bull
US_Bull Dec. 19 at 5:52 PM
$ADAPY I find it odd that Chris has not updated his Linkedin under seperate employment from consultant to permanent CEO under Adaptimmune. It is just stated in his cover under his picture. I wonder if they really are working on getting sold. One would think you would update your position to CEO if you thought you were staying at a place long term.
0 · Reply
US_Bull
US_Bull Dec. 19 at 5:45 PM
$ADAPY They are really trying hard but now with pure nonsense.
1 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 19 at 5:25 PM
$ADAPY Probably the worst biotech story I have ever witnessed. Total incompetence fro the board of directors and especially the former CEO. Total clown.
2 · Reply